Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded. Order reflects our editorial rubric and our commercial relationships; scores are ours alone.
Head-to-head for women
Direct Meds vs SkinnyRx
Direct Meds and SkinnyRx both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Luna Fit Score — our women's-health rubric.
Direct Meds
Higher scoreRanked #26 for women · Grade B−
Luna Fit
Best for: Women who want an oral or sublingual alternative to weekly shots, on an all-inclusive program with no membership fee, and who are comfortable vetting a newer compounder themselves.
FDA warning letterSeptember 2025Read it ↗Visit Direct MedsSkinnyRx
Ranked #56 for women · Grade C
Luna Fit
Best for: Readers treating insulin resistance who want the dual GIP/GLP-1 molecule without a weekly injection, and who will open the plan selector and read the month-to-month rate rather than the advertised one.
FDA warning letterFebruary 2026Read it ↗Visit SkinnyRxThe verdict for women
Direct Meds edges out SkinnyRx on the Luna Fit Score, 80 to 71 (B− vs C). Women who want an oral or sublingual alternative to weekly shots, on an all-inclusive program with no membership fee, and who are comfortable vetting a newer compounder themselves. The reasoning behind that number is in what we found reviewing Direct Meds.
SkinnyRx is still a genuine option — the rare program that compounds tirzepatide as a dissolving tablet as well as an injection — genuinely useful if the needle is what is stopping you — sold behind a four-rung commitment ladder whose cheapest rung is the only price the site ever shows you. Weigh the six women's-health factors below against your own priorities; the SkinnyRx scorecard goes through each of them, and if neither of these two is the one, our ranked shortlist of SkinnyRx alternatives widens the field.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | Direct Meds | SkinnyRx |
|---|---|---|
| Luna Fit Score | 80/100 · B− | 71/100 · C |
| Overall rank | #26 | #56 |
| Semaglutide | $249/mo sublingual · $297/mo injectable | $349/mo month-to-month (from $199/mo on a 12-month plan) — the site displays only the 12-month rate |
| Tirzepatide | $299/mo sublingual · $399/mo injectable | $399/mo month-to-month, injectable or dissolving tablet (from $299/mo on a 12-month plan) — the site displays only the 12-month rate |
| Coverage | Not publicly listed | No state list published; the offer terms report no state restrictions |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Luna Fit
Direct Meds
Ranked #26 · Grade B−
What we like
- Rare oral and sublingual route in addition to injectable — a real option for the needle-averse
- Both molecules offered — semaglutide and tirzepatide for insulin-resistant PCOS
- All-inclusive pricing with no separate membership fee, and a promotional entry near $147
The caveats
- Compounded only — no FDA-approved brand semaglutide or tirzepatide
- Prices are company-stated, not ones we could verify live, and the brand runs multiple domains
- A newer operator with an ambiguous footprint, so the oversight signal is thinner
Luna Fit
SkinnyRx
Ranked #56 · Grade C
What we like
- A compounded tirzepatide TABLET — a dissolving sublingual route for the dual GIP/GLP-1 molecule, priced identically to the injection at every rung, which is close to unique in this ranking
- Both molecules across three routes — injection, sublingual and daily tablet — so needle aversion never means changing provider or dropping back to the single-pathway drug
- Lower-dose "microdose" lines for both molecules are sold as their own products with their own published ladders, rather than being quoted at the full-dose price
The caveats
- Carries an active FDA warning letter issued in February 2026 (see the notice on this page for FDA's own record)
- Every price the site advertises is the TWELVE-MONTH rung: its own headline reads "Starting at $299/mo" while the month-to-month tirzepatide rate is $399 and the renewal price in its code is literally 399 — semaglutide is the same shape at $199 advertised against $349 month-to-month
- The commitment is not named beside the number anywhere in the marketing copy, and the prepay rung is also what its schema.org product markup publishes as the price — so search engines and AI assistants are given the twelve-month rate as though it were the monthly one
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. Pricing, states and verification reflect each provider's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Neither Direct Meds nor SkinnyRx is only worth comparing with the other. Direct Meds is also written up against CoreAge Rx, 13 points apart on the Luna Fit Score — see Direct Meds vs CoreAge Rx for women. SkinnyRx is also written up against CoreAge Rx, 22 points apart — see the SkinnyRx–CoreAge Rx head-to-head.
- Direct Meds vs CoreAge Rx
- Direct Meds vs Enhance MD
- Direct Meds vs Eden
- SkinnyRx vs yourEra
- SkinnyRx vs Sesame Care
- SkinnyRx vs HealthRX
Or browse the full comparison hub.